Larimar Therapeutics Q3 net loss widens

Reuters

2025/11/05

Larimar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss widens

Overview

Larimar reports Q3 net loss of $47.7 mln, driven by increased R&D expenses
Company modifies nomlabofusp dosing to reduce anaphylaxis risk
BLA submission for nomlabofusp targeted for Q2 2026

Outlook

Larimar targets BLA submission for nomlabofusp in Q2 2026
Company plans U.S. launch of nomlabofusp in early 2027
Larimar implementing modified dosing regimen to reduce anaphylaxis risk

Result Drivers

Research and development expenses for the third quarter of 2025 were $44.9 million compared to $13.9 million for the third quarter of 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.61
Q3 Net Income		-$47.71 mln
Q3 Basic EPS		-$0.61
Q3 Income From Operations		-$49.49 mln
Q3 Operating Expenses		$49.49 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Larimar Therapeutics Inc is $17.00, about 77.6% above its November 4 closing price of $3.80

Press Release: ID:nGNXbKrz8r

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581243717"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581243717\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581243717?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581243717","market":"us","top_or_hot":-1,"title":"Larimar Therapeutics Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Larimar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Larimar reports Q3 net loss of $47.7 mln, driven by increased R&amp;D expenses</p></li><li><p>Company modifies nomlabofusp dosing to reduce anaphylaxis risk</p></li><li><p>BLA submission for nomlabofusp targeted for <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Larimar targets BLA submission for nomlabofusp in Q2 2026</p></li><li><p>Company plans U.S. launch of nomlabofusp in early 2027</p></li><li><p>Larimar implementing modified dosing regimen to reduce anaphylaxis risk</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses for the third quarter of 2025 were $44.9 million compared to $13.9 million for the third quarter of 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.61</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$47.71 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.61</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$49.49 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$49.49 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Larimar Therapeutics Inc is $17.00, about 77.6% above its November 4 closing price of $3.80</p></li></ul><p>Press Release: <span>ID:nGNXbKrz8r</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Larimar Therapeutics Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLarimar Therapeutics Q3 net loss widens\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-05 20:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Larimar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Larimar reports Q3 net loss of $47.7 mln, driven by increased R&amp;D expenses</p></li><li><p>Company modifies nomlabofusp dosing to reduce anaphylaxis risk</p></li><li><p>BLA submission for nomlabofusp targeted for <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Larimar targets BLA submission for nomlabofusp in Q2 2026</p></li><li><p>Company plans U.S. launch of nomlabofusp in early 2027</p></li><li><p>Larimar implementing modified dosing regimen to reduce anaphylaxis risk</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses for the third quarter of 2025 were $44.9 million compared to $13.9 million for the third quarter of 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.61</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$47.71 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.61</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$49.49 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$49.49 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Larimar Therapeutics Inc is $17.00, about 77.6% above its November 4 closing price of $3.80</p></li></ul><p>Press Release: <span>ID:nGNXbKrz8r</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LRMR","symbol_name":"Larimar Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0KW:1","article_id":"2581243717","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581243717","pubTimestamp":1762345076,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Larimar Therapeutics Q3 net loss widensOverviewLarimar reports Q3 net loss of $47.7 mln, driven by increased R&D expensesCompany modifies nomlabofusp dosing to reduce anaphylaxis riskBLA submission fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LRMR":"Larimar Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Larimar Therapeutics第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LRMR":0.9},"content_text":"Larimar Therapeutics Q3 net loss widensOverviewLarimar reports Q3 net loss of $47.7 mln, driven by increased R&D expensesCompany modifies nomlabofusp dosing to reduce anaphylaxis riskBLA submission for nomlabofusp targeted for Q2 2026OutlookLarimar targets BLA submission for nomlabofusp in Q2 2026Company plans U.S. launch of nomlabofusp in early 2027Larimar implementing modified dosing regimen to reduce anaphylaxis riskResult DriversResearch and development expenses for the third quarter of 2025 were $44.9 million compared to $13.9 million for the third quarter of 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.61Q3 Net Income-$47.71 mlnQ3 Basic EPS-$0.61Q3 Income From Operations-$49.49 mlnQ3 Operating Expenses$49.49 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Larimar Therapeutics Inc is $17.00, about 77.6% above its November 4 closing price of $3.80Press Release: ID:nGNXbKrz8rFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}